Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CN1-101
Previous Study | Return to List | Next Study

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04418141
Recruitment Status : Recruiting
First Posted : June 5, 2020
Last Update Posted : July 28, 2020
Sponsor:
Collaborator:
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Curon Biopharmaceutical (Australia) Co Pty Ltd

Tracking Information
First Submitted Date  ICMJE May 13, 2020
First Posted Date  ICMJE June 5, 2020
Last Update Posted Date July 28, 2020
Actual Study Start Date  ICMJE July 2, 2020
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 3, 2020)
To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended Phase II dose (RP2D) of CN1 administered to patients with advanced solid tumor or B-cell lymphoma. [ Time Frame: 21 Days after the first dose i.e. starting dose level 0.03 mg/kg ]
DLT is measured in the observation period of 21 days after the first dose i.e. starting dose level 0.03 mg/kg. if the enrolled subject does not experience a study drug related Grade 2 or higher adverse event (AE) per NCI-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, the subject will start to receive the next designated dose level of 0.3 mg/kg in the second 21 days dosing cycle.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 3, 2020)
  • To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Physical Exam [ Time Frame: From baseline(Week 1) to 90 days after the last dose ]
    Measured by incidence of abnormal physical examination findings.
  • To assess the safety and tolerability of CN1 in patients with advanced solid tumor or B-cell lymphoma through Adverse Events/Serious Adverse Events [ Time Frame: From baseline(Week 1) to 90 days after the last dose ]
    Measured by incidence of Adverse Events/Serious Adverse Events. All AEs will be summarized according to the Medical Dictionary for Regulatory Activities (MedDRA) v23.0 or higher and the severity will be categorized by CTCAE v5.0. The summary of all AEs will be focused on the treatment-emergent adverse events (TEAEs). A TEAE is defined as any AE that starts after the first dose of study drug till 90 +/- 7 days after the last dose of study drug.
  • To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Area under the plasma concentration-time curve [ Time Frame: Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks. ]
    The following parameter is used for evaluation during PK assessments: Area under the plasma concentration-time curve (AUC0-t, AUC0- ∞, AUC0-τ)
  • To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Tmax [ Time Frame: Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks. ]
    The following parameter is used for evaluation during PK assessments: Time to maximum (Tmax)
  • To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Apparent volume of distribution at steady state [ Time Frame: Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks. ]
    The following parameter is used for evaluation during PK assessments: Apparent volume of distribution at steady state (Vss)
  • To assess the pharmacokinetic (PK) profile of CN1 in patients with advanced solid tumor or B-cell lymphoma through Accumulation factor based on AUC 0-τ [ Time Frame: Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks. ]
    The following parameter is used for evaluation during PK assessments: Accumulation factor based on AUC 0-τ (R AUC0-τ)
  • To assess the immunogenicity to CN1 in patients with advanced solid tumor or B-cell lymphoma through ADA testing [ Time Frame: Measurement is through treatment completion starting from Week 1 up to End of Treatment, assessed up to an average of 10 weeks. ]
    A validated analysis method will be used for detection of anti-drug antibodies (ADA).
  • To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through ORR analysis [ Time Frame: Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first. ]
    Assessed by the number of participants with objective response (ORR)
  • To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DCR analysis. [ Time Frame: Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first. ]
    Assessed by the number of participants with Disease Control (DCR)
  • To explore the anti-tumor efficacy of CN1 in patients with advanced solid tumor or B-cell lymphoma through DoR analysis. [ Time Frame: Measurement is from Week 1, until the 90 days after the last dose, date of first documented progression or unacceptable toxicity, withdrawal of consent, subject being lost to follow-up, or death, whichever occurs first. ]
    Assessed by the number of participants with Duration of Response (DoR)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Official Title  ICMJE A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma
Brief Summary This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.
Detailed Description

CN1 could promote T cell activation and cytokine secretion, thereby enhancing the function of CD4+ and CD8+ T cells, and could also regulate Treg cells, thus CN1 is considered to enhance the anti-tumor immune response and have potential antitumor activity.

In this multicenter, open-label, dose-escalation Phase I study six dose levels are planned. Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). After completion of treatment cycles, the participant will be assessed by the Principal Investigator and/or Safety Monitoring Committee (SMC).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Advanced Solid Tumor
  • B Cell Lymphoma
Intervention  ICMJE Drug: CN1
Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
Study Arms  ICMJE Experimental: Single Arm

Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.

Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle).

Intervention: Drug: CN1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 3, 2020)
22
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2022
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 75 years old, male or female;
  2. Subjects with histologically or cytologically diagnosed advanced malignant solid tumors or B-cell lymphoma who have failed on, or are intolerant to, standard therapy, for whom there are no standard of care regimens, or who are otherwise not eligible for standard therapy at this stage;
  3. Subjects with Eastern Cooperative Oncology Group (ECOG) performance score of 0-1;
  4. Females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until the end of the follow-up period.
  5. Subjects must be able to understand and sign the paper informed consent before any study specific procedure.

Exclusion Criteria:

  1. Received anti-tumor treatment such as radiotherapy, chemotherapy, biotherapy, endocrine therapy, immunotherapy, etc., within 4 weeks prior to the first dose of study drug.
  2. Received other investigational agents (not yet approved by any regulatory agency) within 4 weeks prior to the first dose of study drug;
  3. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose of study drug;
  4. Systemic application of corticosteroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of study drug;

    • Exceptions: topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, or short-term corticosteroids for prophylaxis (e.g., contrast allergy prophylaxis).
  5. Use of live attenuated vaccine within 4 weeks prior to the first dose of study drug;
  6. Clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the central nervous system or meninges of the subject;
  7. Active infection and in current need of, or likely to need, intravenous anti-infective therapy;
  8. History of immunodeficiency, including history of any positive test result for human immunodeficiency virus (HIV) antibody;
  9. Active hepatitis B or hepatitis C virus infection.
  10. Subjects with active or previous autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except subjects with clinically stable autoimmune thyroid disease;
  11. Subjects with mental disorders or other conditions that pose high non-compliance risks in the opinion of the investigator;
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Danny Zhu +86 138-1074-9637 Danming.Zhu@curonbiopharma.com
Listed Location Countries  ICMJE Austria
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04418141
Other Study ID Numbers  ICMJE CN1-101
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Curon Biopharmaceutical (Australia) Co Pty Ltd
Study Sponsor  ICMJE Curon Biopharmaceutical (Australia) Co Pty Ltd
Collaborators  ICMJE Novotech (Australia) Pty Limited
Investigators  ICMJE
Principal Investigator: John Park Macquarie University Hospital
Principal Investigator: Jim Coward Icon Cancer Centre (Brisbane)
Principal Investigator: Daniel Brungs Illawarra Cancer Care Centre (Wollongong)
Principal Investigator: Gary Richardson Cabrini Hospital (Melbourne)
PRS Account Curon Biopharmaceutical (Australia) Co Pty Ltd
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP